Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial
about
Modulation of deregulated chaperone-mediated autophagy by a phosphopeptideKey issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implicationsUse of biologics in SLE: a review of the evidence from a clinical perspectiveHSPA8/HSC70 chaperone protein: structure, function, and chemical targeting.Immunotherapies in Late-Stage Development for Patients With Severe SLE and/or Lupus Nephritis.Peptides and peptidomimetics as immunomodulators.Pharmacological regulators of autophagy and their link with modulators of lupus diseaseEpigenetics of autoantigens: new opportunities for therapy of autoimmune diseases.The importance of implementing proper selection of excipients in lupus clinical trialsManipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target.Diagnosis and risk stratification in patients with anti-RNP autoimmunity.Mapping epitopes of U1-70K autoantibodies at single-amino acid resolution.Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus.Drugs in early clinical development for Systemic Lupus Erythematosus.Metabolic Factors that Contribute to Lupus PathogenesisConservation of pathogenic TCR homology across class II restrictions in anti-ribonucleoprotein autoimmunity: extended efficacy of T cell vaccine therapy.Ten developments in the use of biologicals for systemic lupus erythematosus.Emerging view of autophagy in systemic lupus erythematosus.Systemic lupus erythematosus: a therapeutic challenge for the XXI century.Emerging biological therapies for systemic lupus erythematosus.Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers.Multifunctional adamantane derivatives as new scaffolds for the multipresentation of bioactive peptides.The evolution of drug discovery in systemic lupus erythematosus.Nanomaterials, Autophagy, and Lupus Disease.What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.Ubiquitin-like protein MNSFβ noncovalently binds to molecular chaperone HSPA8 and regulates osteoclastogenesis.Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.Recent advances and current state of immunotherapy in systemic lupus erythematosus.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.Update on Biologic Therapies for Systemic Lupus Erythematosus.Autophagy: controlling cell fate in rheumatic diseases.T-cell-directed therapies in systemic lupus erythematosus.Regulatory T Cells in SLE: Biology and Use in Treatment.Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.Novel Treatments in Lupus.Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.Capability of Neutrophils to Form NETs Is Not Directly Influenced by a CMA-Targeting PeptideThe human VGF-derived bioactive peptide TLQP-21 binds heat shock 71 kDa protein 8 (HSPA8)on the surface of SH-SY5Y cells
P2860
Q24320133-2878FB75-2ADB-456C-A27D-7ABF5D88EF97Q26775756-14F4F7FA-AD81-4DD4-874C-9B85984169F1Q26783652-9D39CBD9-528C-4677-B013-24DB2BC831EDQ30354473-FB3242BC-DFD2-48C6-B709-361D99F35C10Q33714219-275A47F2-EBB2-4CFB-8BE6-F1B6D1ACCBB7Q34359984-7AA7FE1C-B661-4BBD-90C1-DC3F9744023EQ34402759-97D32E8D-CE83-49AB-8D10-9FF8BCD65DEDQ34463063-860B420C-037A-4CD4-BA58-3369A94DFD8FQ34512785-6472F9C3-CFC5-4C69-8499-7D70310ACF16Q35622999-AE1297EB-7007-4431-9E66-1F2D25161056Q35930490-61158E98-9074-44B8-80DD-9CB54553EFD6Q36751110-7509BDFB-37FB-4B53-8656-07C9D59F8D50Q37150868-D84D7869-C156-4D9A-A691-5BAA45AB8166Q37324772-6F882492-66F5-4339-B571-314D5558C0C0Q37612885-556A64CE-41A4-4412-B108-D1E2A03E068EQ37726019-37044963-6DC0-41D3-BE48-D04DC72DFD69Q38105959-20C80191-B414-421D-A5B8-6C80E68FF1DAQ38189443-9E9613FF-6669-4567-98AC-2B4DAAFCF0D6Q38191835-C97F2D4B-C7CC-4A99-A180-1A760816584DQ38192683-9B784034-E8A7-4C26-AF04-74E69B4B0A99Q38247180-D9187078-9199-4B67-9F34-32043F0C24A5Q38275427-4190F63D-DE94-4AEB-A632-7AD6BD9E897DQ38540167-6DFA25B4-F2FD-4CCE-97BC-F39EEEA567A8Q38551098-D7A1EA48-2288-4039-BC7C-88DE3CD2AAAFQ38590248-EC51B0E0-EBAE-4656-9ABE-F0634D2362DCQ38690844-36DB14B4-02AD-4D3B-9CB4-C0A290F8DDB3Q38747383-0D91DDCF-08F0-461A-A87C-D8A1968DC895Q38748825-E95D63A1-4F2B-4BF0-98D2-D4B9BD2F9DB4Q38771936-CF00F3B3-FA7C-4486-B851-F2DFECC2A36FQ38794663-057BF958-C7E2-43B6-B4DB-4E1470E752DEQ38840646-11DAF160-D2BC-44FD-B431-A38350E77E5FQ38864797-0C27CC3B-4A77-4895-ACA6-4ED3A6BA2417Q38873681-C5FAA337-F8E6-4B5C-85BF-C68864AC215BQ38920440-644969A5-E110-4D58-B46D-23E232AF6146Q38972466-538D5310-B913-4AE9-9010-B73D3AF1543FQ39150632-65829668-FC4A-4B63-931D-CF92828A9347Q39164953-C4AF71AC-7368-491A-9019-824856E0CE26Q39379152-24B139BD-0AD4-4049-8FD5-7E198F783541Q42327818-2BA2171C-A1BB-4E65-8B21-760D7DE6694AQ42362126-6FBB4AAD-7C44-427E-AAB9-C71C35F89DDC
P2860
Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Lupuzor/P140 peptide in patien ...... olled phase IIb clinical trial
@en
Lupuzor/P140 peptide in patien ...... lled phase IIb clinical trial.
@nl
type
label
Lupuzor/P140 peptide in patien ...... olled phase IIb clinical trial
@en
Lupuzor/P140 peptide in patien ...... lled phase IIb clinical trial.
@nl
prefLabel
Lupuzor/P140 peptide in patien ...... olled phase IIb clinical trial
@en
Lupuzor/P140 peptide in patien ...... lled phase IIb clinical trial.
@nl
P2093
P2860
P1476
Lupuzor/P140 peptide in patien ...... olled phase IIb clinical trial
@en
P2093
Hugo R Scherbarth
Juan Jesus Gomez-Reino
Oscar Luis Rillo
Robert Zimmer
Sylviane Muller
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-202460
P407
P577
2012-11-21T00:00:00Z